MDM2, MDMX and p53 in oncogenesis and cancer therapy

Cited by (998)

Items 301–400 of 998

1. A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
   Łukasz Skalniak, Ewa Surmiak, Tad A. Holak · 2019 · Expert Opinion on Therapeutic Patents
2. Small-molecule correctors and stabilizers to target p53
   Fallatah, Maryam M.J., Law, Fiona V., Chow, Warren A., Kaiser, Peter · 2023 · Trends in Pharmacological Sciences
3. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
   Sriraman, Anusha, Radovanovic, Marija, Wienken, Magdalena, Najafova, Zeynab, Li, Yizhu, Dobbelstein, Matthias · 2016 · Oncotarget
4. Mdm2 as a chromatin modifier
   Magdalena Wienken, Ute Martha Moll, Matthias Dobbelstein · 2016 · Journal of Molecular Cell Biology
5. SIRT3 deacetylates and promotes degradation of P53 in PTEN-defective non-small cell lung cancer
   Yanlu Xiong, Lei Wang, Shan Wang, Mingxing Wang, Jinbo Zhao, Zhipei Zhang, Xiaofei Li, Lintao Jia, Yong Han · 2017 · Journal of Cancer Research and Clinical Oncology
6. MDM2 Amplification in Intrahepatic Cholangiocarcinomas
   Sung Joo Kim, Masayuki Akita, You‐Na Sung, Kohei Fujikura, Jae Hoon Lee, Shin Hwang, Eunsil Yu, Kyoko Otani, Seung‐Mo Hong, Yoh Zen · 2018 · The American Journal of Surgical Pathology
7. Inhibition of mutant Kras and p53‐driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53
   Dandan Xu, Xin Tong, Leyu Sun, Haonan Li, Ryan Jones, Jie Liao, Guang‐Yu Yang · 2019 · Molecular Carcinogenesis
8. Donut‐Shaped Stretchable Kirigami: Enabling Electronics to Integrate with the Deformable Muscle
   Yusuke Morikawa, Shota Yamagiwa, Hirohito Sawahata, Rika Numano, Kowa Koida, Takeshi Kawano · 2019 · Advanced Healthcare Materials
9. A general-purpose Nanohybrid fabricated by Polymeric Au(I)-peptide precursor to wake the function of Peptide Therapeutics
   Jin Yan, Fanpu Ji, Siqi Yan, Weiming You, Fang Ma, Fanni Li, Yinong Huang, Wenjia Liu, Wangxiao He · 2020 · Theranostics
10. Targeting mechanosensitive MDM4 promotes lung fibrosis resolution in aged mice
    Jing Qu, Shanzhong Yang, Yi Zhu, Ting Guo, Victor John Thannickal, Yong Zhou · 2021 · The Journal of Experimental Medicine
11. MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4
    Lynnette Marcar, Bianca Ihrig, John M Hourihan, Susan E. Bray, Philip Quinlan, Lee B. Jordan, Alastair Mark Thompson, Ted R. Hupp, David W. Meek · 2015 · PLoS ONE
12. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins
    Joana Soares, Liliana Raimundo, Nuno A. L. Pereira, Daniel J. V. A. dos Santos, Maria Pérez, Glória Queiróz, Mariana Leão, Maria M. M. Santos, Lucı́lia Saraiva · 2015 · Pharmacological Research
13. Disruption of apoptosis pathways involved in zebrafish gonad differentiation by 17α-ethinylestradiol and fadrozole exposures
    Ana Luzio, Manuela Matos, Dércia Santos, A. Fontaínhas‐Fernandes, Sandra Mariza Monteiro, Ana Maria Coimbra · 2016 · Aquatic Toxicology
14. Pleckstrin homology domain-containing protein PHLDB3 supports cancer growth via a negative feedback loop involving p53
    Tengfei Chao, Xiang Yu Zhou, Bo Cao, Peng Liao, Hongbing Liu, Yun Chen, Hee‐Won Park, Shelya X. Zeng, Hua Lu · 2016 · Nature Communications
15. Anti-Tumorigenic Activity of Chrysin from Oroxylum indicum via Non-Genotoxic p53 Activation through the ATM-Chk2 Pathway
    Mai Nagasaka, Ryoko Hashimoto, Yasumichi Inoue, Kan’ichiro Ishiuchi, Michiyo Matsuno, Yuka Itoh, Muneshige Tokugawa, Nobumichi Ohoka, Daisuke Morishita, Hajime Mizukami et al. · 2018 · Molecules
16. Drug-adapted cancer cell lines as preclinical models of acquired resistance
    Martin Michaelis, Mark N. Wass, Jindrich Jr. Cinatl · 2019 · Cancer Drug Resistance
17. Long Noncoding RNA PVT1 Silencing Prevents the Development of Uveal Melanoma by Impairing MicroRNA-17-3p–Dependent MDM2 Upregulation
    Shuai Wu, Han Chen, Ning Han, Chunxia Zhang, Hong-tao Yan · 2019 · Investigative Ophthalmology & Visual Science
18. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma
    Sarah E. Woodfield, Yan Ping Shi, Roma H. Patel, Zhenghu Chen, Aayushi P. Shah, Rohit Kumar Srivastava, Richard S. Whitlock, Aryana M. Ibarra, Samuel R. Larson, Stephen Frederick Sarabia et al. · 2021 · Scientific Reports
19. Targeting Mdmx to treat breast cancers with wild-type p53
    Sue Haupt, D Buckley, J-MB Pang, J Panimaya, Piotr Jan Paul, Cristina Gamell, Elena A. Takano, Y Ying Lee, Sanne Hiddingh, T-M Rogers et al. · 2015 · Cell Death and Disease
20. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression
    Xiang Li, Neelakshi Gohain, Si Chen, Yinghua Li, Xiaoyuan Zhao, Bo Li, William David Tolbert, Wangxiao He, Marzena Pazgier, Honggang Hu et al. · 2021 · Acta Pharmaceutica Sinica B
21. Sirtuin1-p53: A potential axis for cancer therapy
    Jiayi Yin, Xin-tong Lu, Meng-Ling Hou, Ting Cao, Zhen Tian · 2023 · Biochemical Pharmacology
22. Reactivation of p53 as therapeutic intervention for malignant melanoma
    Aart G. Jochemsen · 2013 · Current Opinion in Oncology
23. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer
    Wendy M. Swetzig, Jianmin Wang, Gokul M. Das · 2016 · Oncotarget
24. Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis
    Jiang‐Jiang Qin, Wei Wang, Sushanta Sarkar, Ruiwen Zhang · 2016 · Journal of Controlled Release
25. Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics
    Wangxiao He, Jin Yan, Yujun Li, Siqi Yan, Simeng Wang, Peng Hou, Wuyuan Lu · 2020 · Journal of Controlled Release
26. Tp53 Suppression Promotes Cardiomyocyte Proliferation during Zebrafish Heart Regeneration
    Adam R. Shoffner, Valentina Cigliola, Nutishia Lee, Jianhong Ou, Kenneth D. Poss · 2020 · Cell Reports
27. Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
    Chiao‐En Wu, Yi‐Ru Pan, Chun‐Nan Yeh, John Lunec · 2020 · Biomolecules
28. Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier
    Kim, Minjee, Ma, Daniel J., Calligaris, David, Zhang, Shuangling, Feathers, Ryan W., Vaubel, Rachael A., Meaux, Isabelle, Mladek, Ann C., Parrish, Karen E., Jin, Fang et al. · 2018 · Molecular Cancer Therapeutics
29. The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update
    Maysaloun Merhi, Fareed Ahmad, Nassiba Taib, Varghese Philipose Inchakalody, Shahab Uddin M.S., Alaaeldin Shablak, Said Dermime · 2023 · Seminars in Cancer Biology
30. ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1
    Oriol de Barrios, Balázs Győrffy, María Jesús Fernández‐Aceñero, Ester Sànchez‐Tilló, Lidia Sánchez-Moral, Laura Siles, Anna Esteve‐Arenys, Gaël Roué, José Ignacio Casal, Douglas S. Darling et al. · 2016 · Gut
31. Enhanced anticancer effects of Scutellaria barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells
    Qian Wang, Narayan Acharya, Zhongwei Liu, Xianmei Zhou, Meghan M. Cromie, Jia Zhu, Weimin Gao · 2018 · Journal of Ethnopharmacology
32. Acute HSF1 depletion induces cellular senescence through the MDM2-p53-p21 pathway in human diploid fibroblasts
    Tsukasa Oda, Takayuki Sekimoto, Kiminori Kurashima, Mitsuaki Fujimoto, Akira Nakai, Takayuki Yamashita · 2018 · Journal of Cell Science
33. Peptide-Induced Self-Assembly of Therapeutics into a Well-Defined Nanoshell with Tumor-Triggered Shape and Charge Switch
    Wangxiao He, Jin Yan, Wei Jiang, Shichao Li, Yiping Qu, F. Niu, Yuwei Yan, Fang Sui, Simeng Wang, Yi Zhou et al. · 2018 · Chemistry of Materials
34. Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo
    Yamini M. Ohol, Michael T. Sun, Gene Cutler, Paul R. Leger, Dennis X. Hu, Bérenger Biannic, Payal Rana, Cynthia Cho, Scott Jacobson, Steve Wong et al. · 2020 · Molecular Cancer Therapeutics
35. Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment
    Racheal Louise Johnson, Michele Cummings, Amudha Thangavelu, Georgios Theophilou, Diederick De Jong, Nicolas Michel Orsi · 2021 · Cancers
36. A small-molecule inhibitor of MDMX suppresses cervical cancer cells via the inhibition of E6-E6AP-p53 axis
    Jingwen Zhang, Guohua Yu, Yanting Yang, Yingjie Wang, Mengqi Guo, Qikun Yin, Chunhong Yan, Jingwei Tian, Fenghua Fu, Hongbo Wang · 2022 · Pharmacological Research
37. Deubiquitinases in Neurodegeneration
    Abudu I. Bello, Rituparna Goswami, Shelby L. Brown, Kara M. Costanzo, Taylor Shores, Shefaa K. Allan, Revan Odah, Ryan D. Mohan · 2022 · Cells
38. Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup
    Jen‐Chieh Lee, Tzu‐Pin Lu, Chun A. Changou, Cher‐Wei Liang, Hsien‐Neng Huang, Alexandra Lauria, Hsuan‐Ying Huang, Chin-Yao Lin, Ying‐Cheng Chiang, Ben Davidson et al. · 2016 · Modern Pathology
39. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX–MDM2 complex
    Anna de Polo, Zhongling Luo, Casimiro Gerarduzzi, Xiang Chen, John B. Little, Zhi-Min Yuan · 2016 · Journal of Molecular Cell Biology
40. Dual regulation of p53 by the ribosome maturation factor SBDS
    Qian Hao, Jieqiong Wang, Yajie Chen, Shanshan Wang, Mingming Cao, Hua Lu, Xiang Yu Zhou · 2020 · Cell Death and Disease
41. Roles of NRF3 in the Hallmarks of Cancer: Proteasomal Inactivation of Tumor Suppressors
    Akira Kobayashi · 2020 · Cancers
42. Hyperprogression: A novel response pattern under immunotherapy
    Xuejiao Han, Aqu Alu, Yinan Xiao, Yu‐quan Wei, Xia‐wei Wei · 2020 · Clinical and Translational Medicine
43. The Interplay between T Cells and Cancer: The Basis of Immunotherapy
    Christina Chen, Xin Liu, Che‐Yu Chang, Helen Y. Wang, Rong‐Fu Wang · 2023 · Genes
44. Advances in blood–brain barrier-crossing nanomedicine for anti-glioma
    Dongdong Liu, Xingliang Dai, Zhenchao Tao, Hu Zhou, Wenqing Hong, Haisheng Qian, Hongwei Cheng, Xianwen Wang · 2023 · Cancer Nanotechnology
45. Molecular concepts in the pathogenesis of ameloblastoma: Implications for therapeutics
    Tania Jhamb, Jill M. Kramer · 2014 · Experimental and Molecular Pathology
46. Transcription factors and chromatin proteins as therapeutic targets in cancer
    Simon J. Johnston, Jason S. Carroll · 2015 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
47. Analysis of MDM2 Amplification in 43 Endometrial Stromal Tumors
    J. Kenneth Schoolmeester, Andrew P. Sciallis, Patricia Theresa Greipp, Jennelle C. Hodge, Paola Dal Cin, Gary L. Keeney, Marisa R. Nucci · 2015 · International Journal of Gynecological Pathology
48. MDM4 is a rational target for treating breast cancers with mutant p53
    Panimaya Jeffreena Miranda, D Buckley, Dinesh Raghu, Jia‐Min Pang, Elena A. Takano, Reshma Vijayakumaran, Amina F.A.S. Teunisse, Atara Posner, Tahlia Procter, Marco J. Herold et al. · 2017 · The Journal of Pathology
49. A tetrameric protein scaffold as a nano-carrier of antitumor peptides for cancer therapy
    Bohan Ma, F. Niu, Xiaoyan Qu, Wangxiao He, Chao Feng, Simeng Wang, Zhenlin Ouyang, Jin Yan, Yurong Wen, Dan Xu et al. · 2019 · Biomaterials
50. A p53/lnc‐Ip53 Negative Feedback Loop Regulates Tumor Growth and Chemoresistance
    Lizhen Zhang, Jin‐E Yang, Yuwei Luo, Fengting Liu, Yunfei Yuan, Shi‐Mei Zhuang · 2020 · Advanced Science
51. EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma
    Jie Ding, Xiaolong Li, Sabbir Khan, Chen Zhang, Feng Gao, Shayak Sen, Amanda R. Wasylishen, Yang Zhao, Guillermina Lozano, Dimpy Koul et al. · 2022 · Neuro-Oncology
52. Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
    Ulrike Kaindl, M Morak, Craig Portsmouth, A Mecklenbräuker, Max Kauer, Marion Zeginigg, Andishe Attarbaschi, Oskar A. Haas, Renate Panzer‐Grümayer · 2013 · Leukemia
53. SOX4 inhibits GBM cell growth and induces G0/G1 cell cycle arrest through Akt-p53 axis
    Jing Zhang, Huawei Jiang, Jiaofang Shao, Ruifang Mao, Jie Liu, Yingying Ma, Xuefeng Fang, Na Zhao, Shu Sen Zheng, Biaoyang Lin · 2014 · BMC Neurology
54. Substrate and Functional Diversity of Protein Lysine Post-translational Modifications
    Bingbing Hao, Kaifeng Chen, Linhui Zhai, Muyin Liu, Bin Liu, Minjia Tan · 2024 · Genomics Proteomics & Bioinformatics
55. Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
    Cristina Trejo‐Solís, Rosa Angélica Castillo‐Rodríguez, Norma Serrano-García, Daniela Silva‐Adaya, Salvador Vargas-Cruz, Elda Georgina Chávez-Cortéz, Juan Carlos Gallardo‐Pérez, Sergio Zavala-Vega, Arturo Cruz-Salgado, Roxana Magaña-Maldonado · 2024 · Metabolites
56. USP22 Promotes NSCLC Tumorigenesis via MDMX Up-Regulation and Subsequent p53 Inhibition
    Fangbao Ding, Chunrong Bao, Yue Tian, Haibo Xiao, Mingsong Wang, Xiao Xie, Fengqing Hu, Ju Mei · 2014 · International Journal of Molecular Sciences
57. Switching on p53: an essential role for protein phosphorylation?
    Jayne Loughery, David W. Meek · 2013 · Biodiscovery
58. Genotoxic potential of the binary mixture of cyanotoxins microcystin-LR and cylindrospermopsin
    Klara Hercog, Sara Maisanaba, Metka Filipič, Angeles M. Jos, Ana Maria Cameán, Bojana Žegura · 2017 · Chemosphere
59. Upregulation of circular RNA circ‑FAM53B predicts adverse prognosis and accelerates the progression of ovarian cancer via the miR‑646/VAMP2 and miR‑647/MDM2 signaling pathways
    Dan Sun, Jianing Liu, Lili Zhou · 2019 · Oncology Reports
60. Mdm2: Open questions
    Matthias Dobbelstein, Arnold J. Levine · 2020 · Cancer Science
61. Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy
    Tingting Liu, Zhongyu Wu, Yujing He, Yuliang Xiao, Chengcai Xia · 2020 · European Journal of Medicinal Chemistry
62. Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53–MDM2 interaction
    Chong Li, Changyou Zhan, Le Zhao, Xishan Chen, Weiyue Lu, Wuyuan Lu · 2013 · Bioorganic & Medicinal Chemistry
63. Novel Insights into Chk1 Regulation by Phosphorylation
    Hidemasa Goto, Kousuke Kasahara, Masaki Inagaki · 2014 · Cell Structure and Function
64. Different stapling-based peptide drug design: Mimicking α-helix as inhibitors of protein–protein interaction
    Xiang Li, Yan Zou, Honggang Hu · 2018 · Chinese Chemical Letters
65. Lymphomas driven by Epstein–Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2
    Sana Saeed Alqarni, Yazeed A. Al‐Sheikh, Donald Campbell, Mark E. Drotar, Adèle Hannigan, Shelagh Boyle, Pawel Herzyk, Andrew V. Kossenkov, Kate Armfield, Lauren Jamieson et al. · 2018 · Oncogene
66. Aging tumour cells to cure cancer: “pro-senescence” therapy for cancer
    Arianna Calcinotto, Andrea Alimonti · 2017 · Swiss Medical Weekly
67. MDM2-mediated degradation of WRN promotes cellular senescence in a p53-independent manner
    Boya Liu, Jingjie Yi, Xin Ping Yang, Lu Liu, Xinlin Lou, Zeyuan Zhang, Hao Qi, Zhe Wang, Junhua Zou, Wei‐Guo Zhu et al. · 2018 · Oncogene
68. Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer
    Zhihao Lü, Jianling Zou, Ying Hu, Shuang Li, Tao You Zhou, Jifang Gong, Jian Li, Xiaotian Zhang, Jun Zhou, Ming Shian Lu et al. · 2019 · JAMA Network Open
69. Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway
    Yueming Chen, Huachao Li, Weinan Zhang, Wanchen Qi, Changpeng Lu, Huiliang Huang, Zhicheng Yang, Bing Liu, Luyong Zhang · 2019 · Toxicology and Applied Pharmacology
70. WDR74 modulates melanoma tumorigenesis and metastasis through the RPL5–MDM2–p53 pathway
    Yumei Li, Yu Zhou, Bifei Li, Fan Chen, Weiyu Shen, Yusheng Lu, Chunlian Zhong, Chen Zhang, Huanzhang Xie, Vladimir L. Katanaev et al. · 2020 · Oncogene
71. The Emerging Roles of circFOXO3 in Cancer
    Dean Rao, Chengpeng Yu, Jiaqi Sheng, Enjun Lv, Wenjie Huang · 2021 · Frontiers in Cell and Developmental Biology
72. Dying to Survive—The p53 Paradox
    Andrea Lees, Tamas Sessler, Simon S. McDade · 2021 · Cancers
73. RIOK1 mediates p53 degradation and radioresistance in colorectal cancer through phosphorylation of G3BP2
    Yaqi Chen, Sha Zhou, Kairui Wan, Long Yu, Chongchong Zhao, Haiteng Deng, Qingjian Ou, Jiayi Qin, Junbo Hu, Zhenlin Hou · 2022 · Oncogene
74. Tetra-substituted imidazoles as a new class of inhibitors of the p53–MDM2 interaction
    Andrea Vaupel, Guido Bold, Alain De Pover, Therese‐Marie Stachyra, Joanna Hergovich Lisztwan, Joerg A. Kallen, Keiichi Masuya, Pascal Furet · 2014 · Bioorganic & Medicinal Chemistry Letters
75. Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma
    Claire Worrall, Naida Suleymanova, Caitrin Crudden, Iara Trocoli Drakensjo, Elisabeta Candrea, Daniela Nedelcu, S-I Takahashi, Leonard Girnita, Ada Girnita · 2017 · Oncogene
76. Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma
    Hao Wu, Wenwen Gao, Peng Chen, Yao Wei, Haikang Zhao, Fenglu Wang · 2024 · Heliyon
77. Hepatocyte Nuclear Factor 6 Suppresses the Migration and Invasive Growth of Lung Cancer Cells through p53 and the Inhibition of Epithelial-Mesenchymal Transition
    Xinwang Yuan, Dongmei Wang, Ying Hu, Yun-Neng Tang, Weiwei Shi, Xiaojie Guo, Jianguo Song · 2013 · Journal of Biological Chemistry
78. Molecular Pathways: Harnessing E2F1 Regulation for Prosenescence Therapy in p53-Defective Cancer Cells
    Anni Laine, Jukka K. Westermarck · 2014 · Clinical Cancer Research
79. Genomics of Squamous Cell Lung Cancer
    Melissa Rooney, Siddhartha H. K. Devarakonda, Ramaswamy Govindan · 2013 · The Oncologist
80. Inhibition of FOXQ1 induces apoptosis and suppresses proliferation in prostate cancer cells by controlling BCL11A/MDM2 expression
    Xiang Zhang, Lijuan Wang, Yingmei Wang, Shenjia Shi, Huayu Zhu, Fengjin Xiao, Jing Yang, Angang Yang, Xiaoke Hao · 2016 · Oncology Reports
81. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction
    Ewa Surmiak, Aleksandra Twarda‐Clapa, Krzysztof M. Żak, Bogdan Musielak, Marcin D. Tomala, Katarzyna Kubica, P. Grudnik, Mariusz Madej, Mateusz Jabłoński, Jan Potempa et al. · 2016 · ACS Chemical Biology
82. A Novel Role for Pyruvate Kinase M2 as a Corepressor for P53 during the DNA Damage Response in Human Tumor Cells
    Xia Li, Xinran Wang, Xiaoling Wang, Su-Hui Liu, Xiaowei Ding, Guoqiang Chen, Ying Lu · 2016 · Journal of Biological Chemistry
83. Negative auto-regulators trap p53 in their web
    Xiang Yu Zhou, Bo Cao, Hua Lu · 2017 · Journal of Molecular Cell Biology
84. Optimal Affinity Enhancement by a Conserved Flexible Linker Controls p53 Mimicry in MdmX
    Wade M. Borcherds, Andreas Becker, Lihong Chen, Jiandong Chen, Lucia Beatriz Chemes, Gary W. Daughdrill · 2017 · Biophysical Journal
85. HOXA10 knockdown inhibits proliferation, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells through HDAC1
    Yi Zhang, Jie Chen, Shanshan Wu, Mengjiao Lv, Yongsheng Yu, Zhenghao Tang, Xiaohua Chen, Guoqing Zang · 2019 · Cancer Management and Research
86. Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer
    Wen Li, Xinhao Peng, Jinyi Lang, Chuan Shan Xu · 2020 · Frontiers in Pharmacology
87. Emerging roles for HMGA2 in colorectal cancer
    Xin Wang, Jian Wang, Jingjing Wu · 2020 · Translational Oncology
88. The p53-Mdm2 Loop: A Critical Juncture of Stress Response
    Yaara Levav-Cohen, Zehavit Goldberg, Kah Hin Tan, Osnat Alsheich-Bartok, Valentina Zuckerman, Sue Haupt, Ygal Haupt · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
89. JNK–NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress
    Anna Kostecka, Alicja Sznarkowska, Katarzyna Meller, Pilar Acedo, Yao Shi, Habib A. M. Sakil, Anna Kawiak, M. Lion, Aleksandra Królicka, Margareta Wilhelm et al. · 2014 · Cell Death and Disease
90. P53 Regulation-Association Long Non-Coding RNA (LncRNA PRAL) Inhibits Cell Proliferation by Regulation of P53 in Human Lung Cancer
    Pengxiao Su, Fengqin Wang, Bin Qi, Ting Wang, Shaobo Zhang · 2017 · Medical Science Monitor
91. Restoring the switch for cancer cell death: Targeting the apoptosis signaling pathway
    Clement Chung · 2018 · American Journal of Health-System Pharmacy
92. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
    Zhi Ji, Zhi Peng, Jifang Gong, Xiaotian Zhang, Jian Li, Ming Shian Lu, Zhihao Lü, Lin Shen · 2019 · BMC Cancer
93. Zinc-finger protein p52-ZER6 accelerates colorectal cancer cell proliferation and tumour progression through promoting p53 ubiquitination
    Can Huang, Shourong Wu, Wenfang Li, Arin Herkilini, Makoto Miyagishi, Hezhao Zhao, Vivi Kasim · 2019 · EBioMedicine
94. The Basally Expressed p53-Mediated Homeostatic Function
    Isha Nagpal, Zhi-Min Yuan · 2021 · Frontiers in Cell and Developmental Biology
95. The NAD+synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target
    Lu-Zhe Pan, Dae‐Gyun Ahn, Tanveer Sharif, Derek R. Clements, Shashi Ashok Gujar, Patrick W.K. Lee · 2014 · Cell Cycle
96. Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens
    Ali Mohammed Alaseem · 2023 · Saudi Pharmaceutical Journal
97. From foe to friend: Rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor
    Weiming You, Zheng‐Jun Zhou, Zhanfeng Li, Jin Yan, Yang Wang · 2025 · Journal of Pharmaceutical Analysis
98. Monitoring Ligand-Induced Protein Ordering in Drug Discovery
    Christy R. Grace, David Ban, Jaeki Min, Anand Mayasundari, Lie Min, Kristin E. Finch, Lyra M. Griffiths, Nagakumar Bharatham, Donald Bashford, Rodney Kiplin Guy et al. · 2016 · Journal of Molecular Biology
99. Chemical Variations on the p53 Reactivation Theme
    Carlos J. A. Ribeiro, Cecília M. P. Rodrigues, Rui Moreira, Maria M. M. Santos · 2016 · Pharmaceuticals
100. SMG7 is a critical regulator of p53 stability and function in DNA damage stress response
     Hongwei Luo, Lauren E. Cowen, Guowu Yu, Wen G. Jiang, Yi Tang · 2016 · Cell Discovery